Prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort

Abstract

Transcriptomics data from tumor tissue of patients diagnosed with metastatic breast cancer are clustered and associated with overall survival of the patients. A subset of genes from one of the clusterassociated with poor outcome are used to generate a survival prediction model predicting a survival time based on expression levels of a plurality of genes. Using such generated survival prediction model, a survival time of a patient diagnosed with metastatic breast cancer can be predicted and a treatment regimen can be updated or generated based on the survival time.

Description

[0001] This application claims priority to our co-pending U.S. Provisional Applications Serial Nos. 62 / 521,267, filed June 16, 2017 and 62 / 594,345, filed December 4, 2017. technical field [0002] The field of the invention is systems and methods for identifying molecular profiles of metastatic breast cancer that can be used to predict prognosis and / or survival of patients with metastatic breast cancer. Background technique [0003] All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. To the extent that a definition or usage of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and not the definition of that term in that reference. [0004] After first diagnosis, breast cancers are typicall...

AI Technical Summary

Problems solved by technology

[0006] However, in cases where the breast cancer is metastatic, patients often have a very unfavorable prognosis despite the availability of novel targeted therapies

Furthermore, the prognostic and predictive factors for patients with advanced / metastatic breast cancer are not well understood

Indeed, molecular assessment of patients and tumors in the metastatic setting is not routinely performed, although advances in molecular precision medicine have shown enormous benefit for this patient group

[0007] Thus, even though various systems and methods for breast cancer classification are known in the art, the molecular characterization of metastatic breast cancer is not well understood

Images